TheStreet home
TheStreet home
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

LATEST NEWS

Peanut Butter
Play
INVESTING

Allergy-Medication Firm Aimmune Gets Added $200 Million Nestlé Investment

Latest News

PRESS RELEASES

Xencor And Bristol Myers Squibb Enter License Agreement For Use Of Xtend™ XmAb® Technology In SARS-CoV-2 Neutralizing Monoclonal Antibody Combination For The Treatment Of COVID-19

PRESS RELEASES

Xencor Doses First Subject In Phase 1 Study Of XmAb®564, An Engineered IL-2 Cytokine In Development For Autoimmune Diseases

PRESS RELEASES

Xencor To Host First Quarter 2021 Financial Results Webcast And Conference Call On May 5, 2021

PRESS RELEASES

Xencor To Present Preclinical Data From Four Preclinical XmAb® Bispecific Antibody And Cytokine Programs At The American Association For Cancer Research (AACR) Annual Meeting 2021

PRESS RELEASES

Xencor To Present At The Barclays Global Healthcare Conference

PRESS RELEASES

Xencor To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call On February 23, 2021

PRESS RELEASES

Xencor To Present At Upcoming Investor Conferences

PRESS RELEASES

Xencor And MD Anderson Enter Strategic Collaboration To Develop Novel T Cell-Engaging Bispecific Antibodies For Potential Treatment Of Patients With Cancer

PRESS RELEASES

Xencor Enters Collaboration With Janssen With Aim To Discover Novel CD28 Bispecific Antibodies For The Treatment Of Prostate Cancer

PRESS RELEASES

Xencor Presents Updated Data From The Phase 1 Study Of Vibecotamab In Acute Myeloid Leukemia At The 2020 ASH Annual Meeting

PRESS RELEASES

Xencor To Present At Upcoming Investor Conferences

PRESS RELEASES

Xencor, MorphoSys And Incyte Enter Into Global Development Collaboration For Tafasitamab In Combination With Plamotamab

PRESS RELEASES

Xencor Presents Data From Multiple Preclinical XmAb® Bispecific Antibody And Cytokine Programs At The SITC Annual Meeting

PRESS RELEASES

Xencor To Present Data From Phase 1 Study Of Vibecotamab In Acute Myeloid Leukemia At The 2020 ASH Annual Meeting

PRESS RELEASES

Xencor To Host Third Quarter 2020 Financial Results Webcast And Conference Call On November 5, 2020

PRESS RELEASES

Xencor To Present Data From The Phase 1 Study Of XmAb®20717 And Three Research Programs At The SITC Annual Meeting

PRESS RELEASES

Xencor Presents Initial Data From The Phase 1 Study Of Tidutamab In Neuroendocrine Tumors At NANETS' Multidisciplinary NET Medical Virtual Symposium

PRESS RELEASES

Xencor To Present At The 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

PRESS RELEASES

Xencor And MD Anderson Enter Strategic Collaboration To Advance Investigational XmAb® Drug Candidates

PRESS RELEASES

Xencor To Present At Upcoming Investor Conferences

PRESS RELEASES

Xencor Earns Milestone Payment From MorphoSys For FDA Approval Of Monjuvi® (tafasitamab-cxix) In The United States

PRESS RELEASES

Xencor To Host Second Quarter 2020 Financial Results Webcast And Conference Call On August 4, 2020

PRESS RELEASES

Atreca And Xencor Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

PRESS RELEASES

Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies